AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14666741 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control plus Whitening (CTCW)
Number of subjects: 4
Study 14666741 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste (CT)
Number of subjects: 4
Study 14666741 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular (CR)
Number of subjects: 4
Study 14666741 — intervention group
Group type: COMPARATOR
Intervention: Crest Tartar Control (CTC)
Number of subjects: 4
Study 10809298 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional noise cancellation devices
Number of subjects: 0
Study 10809298 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctional noise cancellation devices
Number of subjects: 0
Study 8617188 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (300 ml)
Number of subjects: 10
Study 8617188 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (300 ml)
Number of subjects: 10
Study 8617188 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea with milk (300 ml tea + 100 ml milk)
Number of subjects: 10
Study 8617188 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea with milk (300 ml tea + 100 ml milk)
Number of subjects: 10
Study 8617188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tea)
Number of subjects: 10
Study 1591150 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 0
Study 1591150 — intervention group
Group type: COMPARATOR
Intervention: Conventional long stay hospital wards
Number of subjects: 0
Study 3001562 — intervention group
Group type: EXPERIMENTAL
Intervention: Alsactide (10 or 100 micrograms i.v. as bolus followed by the same dose infused over 2 hours)
Number of subjects: 14
Study 3001562 — intervention group
Group type: EXPERIMENTAL
Intervention: Alsactide (100 micrograms i.v. as bolus plus 100 micrograms infused over 2 hours)
Number of subjects: 14
Study 3001562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30909923 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on phototherapy (one winter under spaced sessions of phototherapy)
Number of subjects: 0
Study 30909923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplementation
Number of subjects: 0
Study 30909923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for vitamin D supplementation)
Number of subjects: 0
Study 30909923 — intervention group
Group type: COMPARATOR
Intervention: Standard care (TAT)
Number of subjects: 0
Study 30711299 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations about the future self
Number of subjects: 68
Study 30711299 — intervention group
Group type: COMPARATOR
Intervention: Conversations about the present self, another child's present self, or another child's future self
Number of subjects: 68
Study 28555205 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drills
Number of subjects: 20
Study 28555205 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Number of subjects: 20
Study 28555205 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 25939333 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic Form A of ponesimod in a capsule, 20 mg
Number of subjects: 26
Study 25939333 — intervention group
Group type: COMPARATOR
Intervention: Polymorphic Form C of ponesimod in a capsule, 20 mg
Number of subjects: 26
Study 25939333 — intervention group
Group type: COMPARATOR
Intervention: Polymorphic Form C of ponesimod in a tablet, 40 mg
Number of subjects: 26
Study 25939333 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic Form C of ponesimod in a capsule, 40 mg
Number of subjects: 26
Study 25939333 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations of ponesimod
Number of subjects: 26
Study 24251085 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise class
Number of subjects: 27
Study 24251085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 21676993 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care management intervention
Number of subjects: 407
Study 21676993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study 19505495 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal number of stimulus presentations per session
Number of subjects: 0
Study 19505495 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying number of trials per session
Number of subjects: 0
Study 19505495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 17014629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.25%
Number of subjects: 20
Study 17014629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 1%
Number of subjects: 20
Study 15228062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 40
Study 15228062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no vitamin supplementation)
Number of subjects: 40
Study 11572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide (pCyc)
Number of subjects: 202
Study 9227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate suppository (2.5 mg/kg)
Number of subjects: 69
Study 9227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine sulphate syrup (2.5 mg/kg)
Number of subjects: 69
Study 9227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (2.5 mg/kg)
Number of subjects: 69
Study 9227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate suppository and chloroquine sulphate syrup
Number of subjects: 69
Study 7965295 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 25
Study 3296793 — intervention group
Group type: EXPERIMENTAL
Intervention: D-phenylalanine (20 mg/kg per day)
Number of subjects: 11
Study 3296793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29402862 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal training (23 participants), rehearsing the PM cue words during intention retention.
Number of subjects: 44
Study 29402862 — intervention group
Group type: COMPARATOR
Intervention: Imagery training (21 participants), vividly imagining a mental picture to memorize the connection between the PM cue words and related actions during intention formation.
Number of subjects: 44
Study 27391972 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with inflammation (CRP > 5 mg/L) and/or malaria parasitaemia
Number of subjects: 1943
Study 27391972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection defined as clinical malaria or parasitaemia with/without fever
Number of subjects: 1943
Study 27391972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection defined using CRP only
Number of subjects: 1943
Study 27391972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection definitions that included parasitaemia (Model 5)
Number of subjects: 1943
Study 24948336 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain foods
Number of subjects: 83
Study 24948336 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain foods
Number of subjects: 83
Study 24948336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D (25‐OHD) levels
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson score
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COPD
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Very severe COPD
Number of subjects: 462
Study 23341971 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history of more than 40 pack years
Number of subjects: 462
Study 22002277 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 32
Study 22002277 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia
Number of subjects: 32
Study 18026891 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.08 mg/kg/day)
Number of subjects: 28
Study 18026891 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28
Study 18026891 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study 15845611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 272
Study 15845611 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 272
Study 12568409 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (n = 151) - 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Number of subjects: 331
Study 12568409 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT (n = 180) - 93 mg calcium alone or in combination with vitamin D3 (100-300 IU)/day
Number of subjects: 331
Study 10860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-based methods
Number of subjects: 0
Study 10860412 — intervention group
Group type: COMPARATOR
Intervention: Various techniques for detecting LRP onset
Number of subjects: 0
Study 9327716 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily)
Number of subjects: 24
Study 9327716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg daily)
Number of subjects: 24
Study 8093403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density of the femoral neck
Number of subjects: 8134
Study 8093403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of femoral neck bone density
Number of subjects: 8134
Study 8093403 — intervention group
Group type: COMPARATOR
Intervention: Bone density measurements at various sites (femoral neck, spine, radius, calcaneus)
Number of subjects: 8134
Study 3306385 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 230
Study 3306385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 28422544 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and coordination exercises
Number of subjects: 0
Study 28422544 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Number of subjects: 0
Study 28422544 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 0
Study 27133791 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term healing group (8 to 10 weeks)
Number of subjects: 44
Study 27133791 — intervention group
Group type: COMPARATOR
Intervention: Long-term healing group (18 to 20 weeks)
Number of subjects: 44
Study 24397981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg per day (n=82)
Number of subjects: 165
Study 22851487 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus premeal glulisine
Number of subjects: 388
Study 22851487 — intervention group
Group type: COMPARATOR
Intervention: Twice‐daily premix 75/25 or 70/30 analog insulin
Number of subjects: 388
Study 15912493 — intervention group
Group type: EXPERIMENTAL
Intervention: Shark cartilage product
Number of subjects: 83
Study 15912493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 12701946 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper Standard Gamble (PSG)
Number of subjects: 64
Study 12701946 — intervention group
Group type: COMPARATOR
Intervention: Standard Gamble (SG)
Number of subjects: 64
Study 12701946 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest PSG
Number of subjects: 64
Study 9803069 — intervention group
Group type: COMPARATOR
Intervention: 25 micrograms of intravaginal misoprostol
Number of subjects: 50
Study 9803069 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of intravaginal misoprostol
Number of subjects: 50
Study 9803069 — intervention group
Group type: COMPARATOR
Intervention: 25 micrograms and 50 micrograms of intravaginal misoprostol
Number of subjects: 50
Study 7637222 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable staples (GIA 75‐.060; United States Surgical Co., Ltd.)
Number of subjects: 20
Study 7637222 — intervention group
Group type: COMPARATOR
Intervention: Un-absorbable staples (Multifire GIS 60 Titanium (3.8mm); United States Surgical Co., Ltd.)
Number of subjects: 20
Study 2676800 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel (4 x 5 mg)
Number of subjects: 69
Study 2676800 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel (4 x 40 mg)
Number of subjects: 69
Study 2676800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 69
Study 350328 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan with pyridoxine and ascorbic acid
Number of subjects: 10
Study 350328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31787454 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 100 μg
Number of subjects: 98
Study 31787454 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl 100 μg
Number of subjects: 98
Study 28985106 — intervention group
Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch (CIA) for a mean period of 5.8 ± 1.27 months
Number of subjects: 28
Study 28985106 — intervention group
Group type: COMPARATOR
Intervention: Conventional leveling and alignment using continuous archwire mechanics for 6.1 ± 0.81 months
Number of subjects: 28
Study 27548306 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 83
Study 27548306 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 83
Study 24064007 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist belt on
Number of subjects: 24
Study 24064007 — intervention group
Group type: COMPARATOR
Intervention: Waist belt off
Number of subjects: 24
Study 24064007 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased waist circumference (WC)
Number of subjects: 24
Study 24064007 — intervention group
Group type: COMPARATOR
Intervention: Normal waist circumference (WC)
Number of subjects: 24
Study 21518152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health trainers (LHT) intervention
Number of subjects: 110
Study 21518152 — intervention group
Group type: COMPARATOR
Intervention: Control group (health promotion literature only)
Number of subjects: 110
Study 20720560 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) 300 mg daily (n=93)
Number of subjects: 186
Study 20720560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=93)
Number of subjects: 186
Study 18467322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100
Study 18467322 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100
Study 18467322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bivalirudin and UFH)
Number of subjects: 100
Study 16085660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/day ganirelix (standard dose)
Number of subjects: 31
Study 16085660 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day ganirelix (high dose)
Number of subjects: 31
Study 16085660 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg/day buserelin (long protocol)
Number of subjects: 31
Study 16085660 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 31
Study 11823391 — intervention group
Group type: EXPERIMENTAL
Intervention: AV‐impulse(TM) (rapid IPC)
Number of subjects: 3
Study 11823391 — intervention group
Group type: EXPERIMENTAL
Intervention: SeQuel(TM) (standard IPC)
Number of subjects: 3
Study 11823391 — intervention group
Group type: COMPARATOR
Intervention: Conventional LPD with IPC devices
Number of subjects: 3
Study 11823391 — intervention group
Group type: EXPERIMENTAL
Intervention: New LPD (Levitator(TM)) with IPC devices
Number of subjects: 3
Study 10065073 — intervention group
Group type: COMPARATOR
Intervention: Database-generated summaries
Number of subjects: 293
Study 10065073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dictation-generated summaries
Number of subjects: 293
Study 7582397 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment
Number of subjects: 0
Study 7582397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol treatment
Number of subjects: 0
Study 7582397 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Number of subjects: 79
Study 2261203 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite RBP
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable RBP
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire plexus affection
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper trunk affection
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower trunk affection
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite level assessment
Number of subjects: 79
Study 2261203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphedema presence
Number of subjects: 79
Study 532690 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine 50 mg three times a day during the first week followed by 100 mg three times a day during the next three weeks
Number of subjects: 32
Study 532690 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 25 mg three times a day during the first week followed by 50 mg three times a day during the following three weeks
Number of subjects: 32
Study 532690 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 32
Study 532690 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 32
Study 30945491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle stimulation at Sihua acupoints combined with chemotherapy (paclitaxel + cisplatin or gemcitabine + cisplatin)
Number of subjects: 60
Study 30945491 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel combined with cisplatin or gemcitabine plus cisplatin (chemotherapy)
Number of subjects: 60
Study 28581209 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (continuous 72-hour intravenous infusion)
Number of subjects: 38
Study 28581209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 38
Study 26531700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment in overweight or obese patients (BMI≥25kg/m²)
Number of subjects: 86
Study 26531700 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta treatment in normal-weight patients (BMI<25kg/m²)
Number of subjects: 86
Study 26531700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment in overweight or obese patients (BMI>25)
Number of subjects: 86
Study 23794458 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 194
Study 23794458 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 194
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 (anti-EGFR monoclonal antibody)
Number of subjects: 18
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 (100 mg/m2)
Number of subjects: 18
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 (250 mg/m2)
Number of subjects: 18
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 (400 mg/m2)
Number of subjects: 18
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 (multiple infusions)
Number of subjects: 18
Study 21051930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009
Number of subjects: 18
Study 19944362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (IVA) administered 12 hours after PCI, twice per day.
Number of subjects: 155
Study 19944362 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (METO) administered 12 hours after PCI, twice per day.
Number of subjects: 155
Study 17717928 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WLC)
Number of subjects: 108
Study 17717928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 108
Study 17717928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (WLC + FLX)
Number of subjects: 108
Study 15547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel school based intervention
Number of subjects: 2678
Study 11505966 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Professional toothbrush
Number of subjects: 85
Study 11505966 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Cross Action toothbrush
Number of subjects: 85
Study 9505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 308
Study 9505916 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 308
Study 7998047 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 10‐40 mg
Number of subjects: 97
Study 7998047 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20‐80 mg
Number of subjects: 97
Study 7998047 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 97
Study 7998047 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 97
Study 2973596 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 157
Study 2973596 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime + tobramycin
Number of subjects: 157
Study 30275095 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered to healthy male volunteers, specific dosage not mentioned.
Number of subjects: 0
Study 30275095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) technique for measuring BNZ levels.
Number of subjects: 0